Abstract: Objective：To evaluate the feasibility of the Ion Torrent PGM^TM sequencing technology for detecting gene mutation in patients with acute myeloid leukemia (AML). Methods: Mutational hotspots of 50 cancer related genes in pretherapeutic bone marrow DNA samples from 27 AML patients were detected by Ion Torrent PGM^TM technology. Then, Sanger sequencing was used to verify the corresponding mutations in FMS-related tyrosine kinase 3 (FLT3) and nucleophosmin 1 (NPM1) genes. Results：Twenty nine mutational sites from 17 of 50 cancer related genes were identified by Ion Torrent PGM^TM technology. There were multiple mutations in the same gene, and most of them were single base substitution. The highest mutation frequency was from NPM1 gene (22.2%) and the following by FLT3 (18.5%). The consistency of Ion Torrent PGM^TM and Sanger sequencing was 100% in NPM1 gene, while in FLT3, one positive for Sanger sequencing but negative for Ion Torrent PGM^TM. Conclusion：Mutation spectrum of AML patients may be obtained during short time by Ion Torrent PGM^TM technology. However, the detection of long fragment insertion or deletion by Ion Torrent PGM^TM needs to be improved.